Gateshead, England (ots/PRNewswire) - Due to the number of product sales enquiries from UK based NHS GP practices, Medify Solutions Limited would like to clarify the product availability situation. The first production release of Medify Remote is scheduled to be utilised at Doncaster Central PCT from 1st September 2006. No live GP practice, PCT sales or installations will occur until this date. Confirming the ...
Macclesfield, England (ots/PRNewswire) - - International Panel of Breast Cancer Specialists Agree: 'With Successful Adjuvant Therapy, Early Breast Cancer is Potentially a Curable Condition.' - ATTN: Health Professional Press - For International Journalists - Not for US Media Today, leading breast cancer experts advised unequivocally that 5 years' ...
Lugano (ots) - New evidences confirm the assets of Original Nimesulide(1): multifactorial pharmacological activity, fast analgesic action, proven clinical efficacy Presented at Helsinn Satellite Symposium "A valuable common approach to the treatment of different pain conditions " 12th International Pain Clinic Congress 2006, World Society of Pain Clinicians Turin (Italy), 4-7 July 2006 New ...
New York (ots/PRNewswire) - - More Than 1.2 Million Europeans Die of Smoking-Related Diseases Each Year; An Estimated US$500 Billion in Global Health-Related Costs by 2010 - Medical Expert: 'Helping smokers quit is one of the most important things a physician can do to improve their patients' overall health and reduce the risk of developing serious ...
Basel, Switzerland (ots/PRNewswire) - Roche announced today that its cancer medicine Tarceva (erlotinib) has received a negative opinion from the European Committee for Medicinal Products for Human Use (CHMP) for use in combination with gemcitabine chemotherapy for the first line treatment of advanced pancreatic ...
Madrid (ots/PRNewswire) - PharmaMar today announces the submission of a Marketing Authorization Application to the European Medicines Agency (EMEA) for Yondelis(R) (trabectedin) as a treatment for soft tissue sarcomas (STS). The application is based on the results of a randomised, Phase II pivotal study of ...
Madrid, Spain (ots/PRNewswire) - Corporate: - Zeltia performs 1-for-50 bonus issue - Group revenues amounted to 42.5 million euro. - Investment in R&D amounted to 24.4 million euro in the first half of 2006. - The net cash position (cash + cash equivalents + current financial assets - short-term borrowings) amounted to 55.3 million euro. PharmaMar: - Excellent results of Yondelis in myxoid ...
Gateshead, England (ots/PRNewswire) - Remote Technology Company Medify Solutions (Pink Sheets: MFYS) is delighted to announce its expansion into the European market with Oracle as business partner, the world's largest enterprise software company. Following the positive collaborative achievements of Medify with ...
Global Lung Cancer Coalition (GLCC)
London (ots/PRNewswire) - The Tempus Journalism Awards, launched earlier this year by the Global Lung Cancer Coalition (GLCC), is the first global initiative to recognise excellence in lung cancer reporting. There are still two months remaining before judging begins - so please continue to send in your submissions. Remember, entries are invited from journalists whose features, commentaries or programmes on lung ...
Toronto (ots/PRNewswire) - Remote technology company Medify International announced today that it is building on its UK collaboration with Oracle, the world's largest enterprise software company, and expanding across Europe. Following the success of its collaborative approach with Oracle in delivering a tried and tested system for remote access to ...
Gateshead, England (ots/PRNewswire) - Medify Solutions Limited (Pink Sheets: MFYS) confirms the scheduled go-live date for MedifyRemote to its NHS customers is 1st September 2006. Executive Chairman Jonathan Bryant said, "The confirmation of the go live date for MedifyRemote is an announcement we have all been waiting for - significant projected revenue, seats and profit realised. With the new product, in-house managed service and the share dividend qualification date ...
The Bill & Melinda Gates Foundation
Seattle (ots/PRNewswire) - - Global network of 16 research teams to tackle critical vaccine design challenges The Bill & Melinda Gates Foundation today announced 16 grants totaling US$287 million to create an international network of highly collaborative research consortia focused on accelerating the pace of HIV vaccine development. The grants will ...
Toronto (ots/PRNewswire) - The board of Medify Solutions Limited has announced the confirmation of the extraordinary share dividend following its European subsidiary float. As stated, all shareholders in Medify Solutions Limited (Pink Sheets: MFYS) will receive a share for share dividend granted on floatation. ...
Basel, Switzerland (ots/PRNewswire) - - Novartis Vaccines on track to be the first to manufacture new cell culture-derived influenza vaccines in the United States - New site to support pandemic preparedness - First submission of a cell culture-derived influenza vaccine in the European ...
Shire Pharmaceuticals Group Plc
Basingstoke, England (ots/PRNewswire) - - New Data Show FOSRENOL Is an Effective Monotherapy - Leading to Improved Phosphate Reduction in Dialysis Patients Previously Receiving Alternative Phosphate Binder Therapies New data show calcium-free FOSRENOL (lanthanum carbonate) further reduces phosphate levels in dialysis patients previously receiving other ...
Toronto (ots/PRNewswire) - Medify Solutions Limited today announces its own in-house product for roll out to the NHS. This new capability will replace the legacy generic solution provided for Medify by Pervasic and specifically focuses on the known requirements of Healthcare professionals and the global delivery of MedifyRemote. The development has been led ...
Lund, Sweden (ots/PRNewswire) - - New Patient Data in COPD Brings Valuable Insight to the Consequences of Exacerbations on Patients' Lives, Demonstrating a Strong Psychological Impairment New data from a multinational, interview-based patient study, published today in the medical journal CHEST, shed light ...
Macclesfield, England (ots/PRNewswire) - - Thousands More Women Will Have the Opportunity to Take 'Arimidex' as Part of Their Breast Cancer Treatment and Improve Their Chances of Living Longer, Cancer Free - For Health Professional and Consumer Press - For International Journalists - Not for US ...
Amsterdam and Algiers, Algeria (ots/PRNewswire) - - The Contract Calls for 7 Million Smart Cards Over Three Years and Designing, Building and Implementing the Smart Card Customisation and Management System Gemalto (Euronext NL0000400653 GTO), a world leader in digital security, announced that it has been ...
London (ots/PRNewswire) - The Shareholder and Directors of London Life and Casualty (Barbados) Corporation (LLCBC) announce the retirement of Philip Young from the position of President and CEO and as a Director. Philip has been an active member of senior management within the London Reinsurance Group (LRG) companies since 1991. He has contributed greatly to ...
Bangalore, India (ots/PRNewswire) - - Company's First Integrated Development Center (IDC) Opens in Bangalore as Part of Strategic Development of its Global Clinical Studies Program GE Healthcare, a division of the General Electric Company (NYSE:GE) today announced the opening of its first ...
Paris (ots/PRNewswire) - Bristol-Myers Squibb announced today that the European Commission has granted an approval for BARACLUDE(R) (entecavir) for the treatment of chronic hepatitis B virus infection. BARACLUDE(R) is an oral antiviral therapy specifically designed to block the replication of hepatitis B ...
Birmingham, England (ots/PRNewswire) - For Non-US Journalists Only - For Severe COPD Patients Treated With Budesonide Added to Either Formoterol (Symbicort, AstraZeneca) and/or a Short Acting Bronchodilator, There is a Reduced Risk of Mortality Compared to Patients Treated With Only Formoterol and/or ...
bioLytical(TM) Laboratories (Inc.)
Richmond, Canada (ots/PRNewswire) - bioLytical(TM) Laboratories announced today, that their INSTI(TM) kit, a rapid HIV antibody test developed by the company, received CE Mark approval in their European Community. "We are delighted to have received CE Mark approval for INSTI," says Robert Mackie, President and CEO. "To have CE Mark approval will now allow us to ...
Amsterdam (ots/PRNewswire) - Data presented at the 2006 European League Against Rheumatism (EULAR) Annual Congress in Amsterdam show that 3 years of treatment with the selective co-stimulation modulator abatacept, maintains improvements in Rheumatoid Arthritis (RA) symptoms, physical function, disease activity ...
Amsterdam (ots/PRNewswire) - New data presented at the 2006 European League Against Rheumatism (EULAR) Annual Congress from the one-year open label extension of the 6-month ATTAIN trial (Abatacept Trial in Treatment of Anti-TNF INadequate responders)[1] in which all patients were treated with abatacept, a ...
Basel, Switzerland (ots/PRNewswire) - The US approval of TMC114 (darunavir), a new boosted protease inhibitor (PI), provides the opportunity to build a potent new treatment combination with the fusion inhibitor FUZEON (enfuvirtide) that can successfully combat the HIV virus in treatment resistant patients. ...
Basel, Switzerland and Amsterdam (ots/PRNewswire) - - First RA Drug to Achieve These Results in Patients With an Inadequate Response to Currently Available Treatments New data presented at the EULAR meeting (European League Against Rheumatism) show for the first time that MabThera (rituximab), a unique B cell targeted therapy, is able to significantly ...
The European Science Foundation (ESF)
Brussels (ots/PRNewswire) - - Europe's Experts in the Field Will Hear the Plan and Discuss the Recommendations at Their Annual Meeting in Amsterdam this Week. The world's largest meeting of experts in rheumatic diseases will today hear and debate calls for a pan-European approach to prioritise and combine ...
Basel, Switzerland (ots/PRNewswire) - - Newest HIV Drug Works Better in Combination With FUZEON(R) The emergence of new HIV treatments, such as boosted protease inhibitors (PI), has led to a change in treatment goals for people living with drug-resistant HIV. Up until recently, it has been reluctantly ...